Mecasermin
Contents
Description
Mecasermin is a recombinant human insulin-like growth factor-1 used for growth failure in children with severe primary IGF-1 deficiency or growth hormone gene deletion. It has been investigated for use in Silver-Russell syndrome patients with IGF-1 deficiency and growth retardation. The drug promotes linear growth by stimulating skeletal, cell, and organ growth.
Indications & Therapeutic Use
severe primary IGF-1 deficiency, growth hormone gene deletion with neutralizing antibodies, growth failure in children
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Mecasermin — GNH India
10 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | mecasermin |
| Brands | 1 brand available |
| Active Ingredient | recombinant human insulin-like growth factor-1 (rhIGF-1) |
| Drug Class | severe primary IGF-1 deficiency |
| Manufacturer | Ipsen |
| Dosage Forms | subcutaneous injection, 10 mg/mL solution |
| Medical Code | H01AC03 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00001562 |
| Countries | 8 countries |